Keros Therapeutics, Inc (NASDAQ:KROS) Poised For Near-Term Upside On Clinical Progress And Strong Cash
![]() |
Keros shows signs of short-term bullish momentum driven by clinical updates and a cash position that exceeds market capitalization; valuation still classifies the company as over-valued by WMDST. |









